207 related articles for article (PubMed ID: 30735902)
1. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
[TBL] [Abstract][Full Text] [Related]
2. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
[TBL] [Abstract][Full Text] [Related]
3. HDAC3 is a critical negative regulator of long-term memory formation.
McQuown SC; Barrett RM; Matheos DP; Post RJ; Rogge GA; Alenghat T; Mullican SE; Jones S; Rusche JR; Lazar MA; Wood MA
J Neurosci; 2011 Jan; 31(2):764-74. PubMed ID: 21228185
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
[TBL] [Abstract][Full Text] [Related]
7. Designing potential HDAC3 inhibitors to improve memory and learning.
Amin SA; Adhikari N; Jha T; Ghosh B
J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
[TBL] [Abstract][Full Text] [Related]
8. Context and Auditory Fear are Differentially Regulated by HDAC3 Activity in the Lateral and Basal Subnuclei of the Amygdala.
Kwapis JL; Alaghband Y; López AJ; White AO; Campbell RR; Dang RT; Rhee D; Tran AV; Carl AE; Matheos DP; Wood MA
Neuropsychopharmacology; 2017 May; 42(6):1284-1294. PubMed ID: 27924874
[TBL] [Abstract][Full Text] [Related]
9. Ligand release mechanisms and channels in histone deacetylases.
Kalyaanamoorthy S; Chen YP
J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
[TBL] [Abstract][Full Text] [Related]
10. Memory Specific to Temporal Features of Sound Is Formed by Cue-Selective Enhancements in Temporal Coding Enabled by Inhibition of an Epigenetic Regulator.
Rotondo EK; Bieszczad KM
J Neurosci; 2021 Nov; 41(44):9192-9209. PubMed ID: 34544835
[TBL] [Abstract][Full Text] [Related]
11. PT3: A Novel Benzamide Class Histone Deacetylase 3 Inhibitor Improves Learning and Memory in Novel Object Recognition Mouse Model.
Pulya S; Mahale A; Bobde Y; Routholla G; Patel T; Swati ; Biswas S; Sharma V; Kulkarni OP; Ghosh B
ACS Chem Neurosci; 2021 Mar; 12(5):883-892. PubMed ID: 33577290
[TBL] [Abstract][Full Text] [Related]
12. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
[TBL] [Abstract][Full Text] [Related]
13. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
14. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
15. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Adhikari N; Jha T; Ghosh B
J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
[TBL] [Abstract][Full Text] [Related]
16. [Structure-activity relationships of histone deacetylase inhibitors].
Tan YM; Huang WY; Yu NF
Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase-3: Friend and foe of the brain.
D'Mello SR
Exp Biol Med (Maywood); 2020 Jul; 245(13):1130-1141. PubMed ID: 32486848
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
[TBL] [Abstract][Full Text] [Related]
20. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
